Abcentra™ Achieves Manufacturing Milestone
Friday December 13, 2019
Clinical-stage biopharmaceutical company completes clinical batch manufacturing in advance of upcoming psoriasis trial
LOS ANGELES (December 13, 2019) – Abcentra™ LLC, a clinical-stage biopharmaceutical company developing first-in-class antibody therapeutics for inflammatory diseases, announced today the manufacturing completion of a clinical batch of drug substance for the company’s lead candidate, Orticumab, in advance of Abcentra™ ’s upcoming phase 2 plaque psoriasis clinical trial, scheduled to begin in 2020. Topline results of the clinical trial are expected to be reported in 2021.
Abcentra™ is developing Orticumab to treat chronic inflammation caused by inflammatory lipids, such as oxidized low density lipoprotein (oxLDL). Oxidized low density lipoprotein is implicated in inflammatory diseases including cardiovascular disease, psoriasis, rheumatoid arthritis, and cancer. Such chronic conditions are often treated through immunomodulating biological drugs which may have serious or fatal side effects related to suppression of the immune system. By targeting inflammation from lipids like oxLDL, Abcentra™ believes the company can treat underlying disease, addressing unmet patient needs safer and more effectively.
“The completion of this milestone is a great step forward in our mission to bring new treatments to patients with serious inflammatory diseases,” said Bert Liang, Chief Executive Officer, Abcentra™ . “The phase 2 trial is a critical step in bringing Orticumab to a patient population with inflammatory skin disease. By targeting a more specific inflammatory disease mediator, oxLDL, we can create a new approach to treating a larger patient population without the immunosuppressive side effects and safety concerns associated with immunomodulators.”
For more information on Abcentra™ ’s lead candidate and to view the company’s pipeline of novel therapeutics, please visit www.abcentra.com.
Abcentra™ is a clinical-stage biopharmaceutical company developing a portfolio of novel antibody therapies for inflammatory diseases. The lead candidate targets oxidized low-density lipoprotein, an inflammatory mediator implicated in chronic inflammatory conditions, including cardiovascular disease, psoriasis, rheumatoid arthritis and cancer.